

Overview

- **B³ Pharma** is a **private late-stage** biopharma company.
- **B³ Pharma** is a **Peptide-Drug-Conjugate** (PDC) platform biotechnology company focused on developing its “plug-and-play” Angiopep peptide technology.
- **B³ Pharma Angiopep-Drug-Conjugates** mediate transport by transcytosis across LRP-1 expressing tissues, such as the Blood-Brain-Barrier (BBB) and Blood-Cerebrospinal-Barrier found within the meningeal tissue that surrounds the vertebrate brain and spinal cord.
- **B³ Pharma** Preclinical, Phase 1 and Phase 2 results showed: i-) permeability of **ANG1005** (Angiopep + Paclitaxel conjugate) across the Blood-Brain-Barrier and, ii-) selective penetration within Breast Cancer Brain Metastases and Leptomeningeal Carcinomatosis (BCBMLC), through LRP-1 receptors expressed within cellular membrane. Once inside these malignant cancer cells, Paclitaxel is finally cleaved from Angiopep backbone by lysosomal esterase.
- **B³ Pharma** has successfully completed a Phase 2 trial for **ANG1005** (Angiopep + Paclitaxel) in Breast Cancer patients with Brain Metastases and Leptomeningeal Carcinomatosis (BCBMLC) and held an end-of-Phase 2 meeting with the FDA.
- **Phase II data** were published in *Clinical Cancer Research*, the official journal of the *American Association for Cancer Research (AACR)*. <https://clincancerres.aacrjournals.org/content/early/2020/01/22/1078-0432.CCR-19-3258>
- ANG1005 received **Orphan Drug Designation** (ODD) in the US for BCBM.
- **B³ Pharma** was granted a **Special Protocol Agreement** (SPA) from FDA for its Phase III trial.
- **Genexi** issued a satisfactory **Certificate of Analysis** (CoA) to manufacture **B³ Pharma's** product as a “Sterile Powder for Solution”, according to GMP standards.
- **B³ Pharma** received a proposal from **IQVIA Biotech** to conduct a Phase III clinical trial at several sites in the U.S. and Europe, enrolling over 156 patients over the next 24 months. IQVIA also authorized **B³ Pharma** to use this proposal to help us raise funds from potential investors.
- **B³ Pharma's patents family**, covering the use of ANG-1005 to treat leptomeningeal carcinomatosis, **expires in 2036**.
- **B³ Pharma** will conduct a pivotal Phase III trial in BCBMLC in the US and Europe starting **Q2 2026**.